NASDAQ:KNSA Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis $24.93 -0.44 (-1.73%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$24.52▼$25.8250-Day Range$18.00▼$27.5552-Week Range$14.12▼$27.92Volume161,896 shsAverage Volume413,706 shsMarket Capitalization$1.77 billionP/E Ratio226.66Dividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Kiniksa Pharmaceuticals alerts: Email Address Kiniksa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside28.4% Upside$32.00 Price TargetShort InterestBearish6.64% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 4 Articles This WeekInsider TradingSelling Shares$6.73 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.06) to $0.59 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.96 out of 5 starsMedical Sector549th out of 910 stocksPharmaceutical Preparations Industry254th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingKiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiniksa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Kiniksa Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.64% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Kiniksa Pharmaceuticals has recently increased by 4.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKiniksa Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KNSA. Previous Next 2.7 News and Social Media Coverage News SentimentKiniksa Pharmaceuticals has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kiniksa Pharmaceuticals this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,727,929.00 in company stock.Percentage Held by Insiders54.57% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kiniksa Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kiniksa Pharmaceuticals are expected to grow in the coming year, from ($0.06) to $0.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals is 226.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals is 226.66, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 112.46.Price to Book Value per Share RatioKiniksa Pharmaceuticals has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kiniksa Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIYou missed the class - here’s your second chanceIt’s time to start your Weekend Side Hustle Right now, some of the HARDEST working folks are getting destroyed by inflation. And that’s left folks looking anywhere they can to generate extra income to cover the bills. It’s almost impossible to keep up with the ever rising costs of living anymore… Most folks think that the ONLY way to generate extra income is by picking up a second job at Costco… Or working overtime hours and late weekend nights. But with what I’m about to share…Click here and I’ll give you the details. About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Read More KNSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNSA Stock News HeadlinesSeptember 5 at 6:37 AM | insidertrades.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Insider John F. Paolini Sells 60,692 SharesSeptember 1, 2024 | insidertrades.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) COO Sells $470,925.00 in StockSeptember 7, 2024 | True Gold Republic (Ad)China Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . September 6 at 4:47 AM | americanbankingnews.comJohn F. Paolini Sells 60,692 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) StockAugust 28, 2024 | wsj.comKiniksa Pharmaceuticals International PLCAugust 28, 2024 | globenewswire.comKiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare ConferenceAugust 22, 2024 | uk.finance.yahoo.comPiramal Pharma Limited (PPLPHARMA.NS)August 20, 2024 | finance.yahoo.comKNSA Sep 2024 25.000 put (KNSA240920P00025000)September 7, 2024 | WealthPress (Ad)This indicator is great for calling bottoms“It was designed to help boost your chances of finding rock solid trade ideas” It’s called the “Master Indicator” And it’s quite possibly one of the most useful indicators you’ll ever use.August 19, 2024 | theglobeandmail.com3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft LandingJuly 25, 2024 | seekingalpha.comKiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call TranscriptJuly 24, 2024 | markets.businessinsider.comBuy Rating for Kiniksa Pharmaceuticals Amidst Strong Arcalyst Performance and Promising Clinical TrialsJuly 24, 2024 | seekingalpha.comKiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 BeatJuly 24, 2024 | msn.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2024 Earnings Call TranscriptJuly 23, 2024 | marketwatch.comKiniksa Pharma Shares Rise 27% After 2Q Earnings, Arcalyst Sales Guidance IncreaseJuly 23, 2024 | seekingalpha.comKiniksa Pharmaceuticals International, plc 2024 Q2 - Results - Earnings Call PresentationJuly 23, 2024 | globenewswire.comKiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio ExecutionJuly 16, 2024 | globenewswire.comKiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024See More Headlines Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/23/2024Today9/07/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KNSA CUSIPN/A CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees220Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$34.00 Low Stock Price Target$30.00 Potential Upside/Downside+28.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio226.66 Forward P/E RatioN/A P/E GrowthN/ANet Income$14.08 million Net Margins-3.10% Pretax Margin-5.32% Return on Equity-7.79% Return on Assets-6.43% Debt Debt-to-Equity RatioN/A Current Ratio3.57 Quick Ratio3.16 Sales & Book Value Annual Sales$338.93 million Price / Sales5.22 Cash FlowN/A Price / Cash FlowN/A Book Value$6.11 per share Price / Book4.08Miscellaneous Outstanding Shares70,940,000Free Float32,228,000Market Cap$1.77 billion OptionableOptionable Beta0.33 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Sanj K. Patel (Age 55)CEO & Chairman of the Board Comp: $1.57MMr. Eben Tessari (Age 42)Senior VP & COO Comp: $733.29kDr. John F. Paolini FACC (Age 59)M.D., Ph.D., Senior VP & Chief Medical Officer Comp: $855.79kMr. Mark Ragosa C.F.A. (Age 50)Senior VP & CFO Mr. Michael R. Megna CPA (Age 53)Chief Accounting Officer & Group VP of Finance Mr. Chad MorinSenior VP & Chief Compliance OfficerMs. Madelyn Demsky Zeylikman (Age 50)SVP, General Counsel & Secretary More ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNOcular TherapeutixNASDAQ:OCULArcutis BiotherapeuticsNASDAQ:ARQTInnovivaNASDAQ:INVAPliant TherapeuticsNASDAQ:PLRXView All CompetitorsInsiders & InstitutionsJohn F PaoliniSold 60,692 sharesTotal: $1.59 M ($26.12/share)Eben TessariSold 17,500 sharesTotal: $470,925.00 ($26.91/share)Driehaus Capital Management LLCSold 6,704 shares on 8/16/2024Ownership: 0.868%Algert Global LLCBought 8,156 shares on 8/16/2024Ownership: 0.026%AQR Capital Management LLCSold 33,328 shares on 8/15/2024Ownership: 0.178%View All Insider TransactionsView All Institutional Transactions KNSA Stock Analysis - Frequently Asked Questions How have KNSA shares performed this year? Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of the year. Since then, KNSA shares have increased by 42.1% and is now trading at $24.93. View the best growth stocks for 2024 here. How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) issued its quarterly earnings results on Tuesday, July, 23rd. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals's revenue was up 51.5% on a year-over-year basis. What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO? 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Kiniksa Pharmaceuticals IPO? Kiniksa Pharmaceuticals (KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals' major shareholders? Kiniksa Pharmaceuticals' top institutional investors include Rubric Capital Management LP (3.41%), Dimensional Fund Advisors LP (0.94%), Millennium Management LLC (0.88%) and Driehaus Capital Management LLC (0.87%). Insiders that own company stock include Eben Tessari, Sanj K Patel, John F Paolini, Mark Ragosa, Michael R Megna and Barry D Quart. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kiniksa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and AbbVie (ABBV). This page (NASDAQ:KNSA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
